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The treatment of meningiomas is tailored to their histological grade. While World Health
Organization (WHO) grade I lesions can be treated with either surgery or external beam
radiation, WHO Grade II and III lesions often require a combination of the two modal-
ities. For these high-grade lesions, conventional external beam radiation is delivered to
either the residual tumor or the surgical resection margin. The optimal timing of radia-
tion, either immediately following surgical resection or at the time of recurrence, is yet
to be determined. Additionally, another method of radiation delivery, brachytherapy, can
be administered locally at the time of surgery for recurrent lesions. Altogether, the com-
plex nature of WHO grade II and III meningiomas requires careful treatment planning and
delivery by a multidisciplinary team.
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Meningiomas are classified morphologically by the World Health
Organization (WHO) grading scheme into three categories (1).
While most meningiomas are benign or grade I, the propensity of
certain subtypes to recur following treatment creates a patholog-
ical course that can lead to a spectrum of malignant disease.
The goal of surgery is to safely resect the tumor and obtain a
diagnosis and pathological grade. Subsequent radiation therapy
depends on the extent of resection and pathological characteris-
tics. Patients harboring either WHO grade II or III meningiomas
have higher recurrence rates, varying between 29–52 and 50–
94% respectively (2–9). This may be due in part to parenchymal
invasion or the aggressiveness of residual tumor cells. Higher
recurrence rates correlate with decreased overall survival (6). The
role of surgery alone is typically inadequate given the high local
recurrence rate. Preliminary observational studies have demon-
strated that radiation improves recurrence rates and overall sur-
vival in these cases (10–12). Therefore, for grade II and grade III
lesions, radiation is often an integral part of any treatment reg-
imen. Radiation is delivered via an external beam source or via
radioactive seeds implanted locally during a surgical procedure
(brachytherapy).
EXTERNAL BEAM RADIATION
Several types of external beam radiation exist, including newer
technologies and delivery techniques such as photon based stereo-
tactic radiosurgery (13–16), hypo-fractionated radiation therapy
(17, 18), and hadron therapy (e.g., proton radiation) (19–22).
Treatment plans may be devised to target the remaining lesional
tissue following subtotal resection, or the resection cavity plus
a margin of approximately 1 cm following gross total resection
of higher grade tumors. Radiation treatment planning requires
balancing the dose and volume delivered for a clinical benefit
with the potential toxicities. Radiation necrosis (22), exacerba-
tion of peritumoral edema (23–25), optic neuropathy (26), cranial
nerve palsy (27), and wound complications are the principle
complications seen following radiation therapy of intracranial
meningiomas.
While the literature is rich with studies on meningiomas, there
is little outcome data available on radiation treatment for WHO
grade II and III meningiomas. All current evidence stems from
retrospective case series, which have been subject to evolution in
treatment methodologies and changes in the grading scheme over
time (1, 28). Nonetheless, radiation therapy, typically administered
as an immediate adjuvant dose (alternatively at the time of recur-
rence) is common for the treatment of these lesions. It should be
noted that since there are no randomized trials, controversy and
differential practice patterns exist with several aspects of radiation
therapy including timing following resection, and best modality
of radiation therapy.
Based upon retrospective data, there is a trend toward improved
outcomes with immediate post-operative radiation following
gross total resection with WHO grade II and III meningiomas.
A single center series analyzed outcomes in 108 patients who
underwent a gross total resection (Simpson grade I) for an atypical
meningioma (2). In this series, the vast majority of patients (100
patients) were treated with surgery alone, while only 8 patients
received immediate adjuvant radiation therapy (stereotactic frac-
tionated radiotherapy) to an approximately 1 cm margin around
the resection cavity. Overall, 30 patients recurred after gross total
resection without adjuvant radiation therapy, whereas none of
the 8 patients who received adjuvant radiation therapy recurred.
Despite this, rates of recurrence between post-operative irradiated
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FIGURE 1 | Management strategy forWHO grade II and III meningioma.
In the typical patient, diagnosis is first obtained by surgery. Post-operative
radiation is administered to decrease the likelihood of recurrence in many
cases and almost universally in cases of subtotal resection. If recurrence
occurs, retreatment with radiation and/or surgery are both viable options
and should be individualized based on the unique clinical scenario.
and non-irradiated patients did not reach statistical significance.
For the entire cohort, the actuarial recurrence rates at 1, 5, and
10 years were 7, 41, and 48%, underscoring the propensity of these
lesions to recur. Disease-specific survival after first recurrence was
86 and 69% at 5 and 10 years, respectively.
In comparison to grade II meningiomas,grade III meningiomas
have a more dismal prognosis, as illustrated in several case series.
In a group of 13 patients with WHO grade III meningiomas
who underwent surgical resection, recurrence occurred in 92%
of patients at a time interval of 0.4–2.8 years (29). The 5- and 8-
year actuarial survival in this group was 47 and 12%, respectively.
Only three of the initial cohort received adjuvant radiation therapy
following primary resection. In another study of grade III menin-
giomas, the 5- and 10-year survival rates were found to be slightly
higher at 64.3 and 34.5%, respectively (9). Despite the aggressive
nature of these tumors, adjuvant radiation therapy is not routinely
administered. One survey reported that only 9 of the 56 studied
centers recommended radiation after gross total resection of an
atypical meningioma (30).
FIGURE 2 | Pre-operative MRI. MRI (l–r, sagittal, axial, coronal)
demonstrates an avidly enhancing, complex falcine meningioma involving
both sides of the superior sagittal sinus.
FIGURE 3 | Post-operative CT scan. Three-dimensional reconstruction
demonstrates both prior craniotomies with microplate fixation, as well as
radioactive brachytherapy seeds placed in the resection cavity.
Undoubtedly, treatment plans for patients are individualized
and based on a multitude of factors. Recent elucidation of the
genomic landscape of these lesions has identified several genetic
subtypes of tumors that may prove to have distinct clinical charac-
teristics and even the potential for response to targeted therapeu-
tics (31–33). Additionally, atypical meningiomas (WHO grade II)
with osseous involvement are associated with poorer outcomes. In
47 patients with atypical meningiomas treated at our institution,
bony involvement was associated with an increased rate of disease
progression and decreased survival (34). Therefore, bone assess-
ment radiographically and histologically is important, and further
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FIGURE 4 | Dosimetry map. A dosimetry map of the radioactive brachytherapy seeds is constructed based on seed arrangement in three-dimensional space.
The red isodose line represents a prescription dose 80 Gy (80% isodose level) whereas the pink isodose line represents a prescription dose of 25 Gy (25%
isodose).
studies should assess the effectiveness of bone resection and/or
targeted radiation therapy to the bone to improve outcome.
BRACHYTHERAPY
Brachytherapy, the local implantation of a radiation source, is con-
sidered “salvage” therapy for the recurrence of aggressive atypical
and anaplastic meningiomas. At the time of re-operation, radioac-
tive sources or “seeds” of iodine-125 are implanted in the resection
cavity in an array that generally generates a median total activity of
between 20 and 60 mCi. Success has been reported with this type
of radiation treatment modality, with early reports of two patients
with recurrent malignant meningiomas having long term remis-
sion after interstitial brachytherapy (35). The largest series to date
(21 patients) reported a median survival following implantation
of 1.6 years for atypical meningioma and 2.4 years for anaplastic
meningioma (36). In this same series, a very high complication rate
was reported, with 27% of patients experiencing radiation necrosis
and 27% with wound complications requiring re-operation.
ONGOING STUDIES
Several trials are studying the role of radiation therapy in the
management of patients with atypical or anaplastic meningiomas.
Some studies are evaluating differences in radiation delivery
modalities and techniques, such as UPCC 24309 (ClinicalTri-
als.gov Identifier: NCT01117844). In this trial,outcomes from pro-
ton beam therapy will be compared to historical controls associ-
ated with conventional photon beam treatment. Other studies aim
to determine the efficacy of immediate post-operative radiation
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therapy of meningiomas following resection. One trial conducted
by the Radiation Therapy Oncology Group (protocol RTOG 0539,
ClinicalTrials.gov Identifier: NCT00895622) is monitoring low-
grade meningiomas (WHO Grade I) with clinical observation fol-
lowing initial surgery, while those with intermediate or high-risk
disease (such as all WHO grade II and III meningiomas) receive
6 weeks of radiation therapy using either three-dimensional
conformal RT or intensity-modulated radiation therapy.
The other study, run by the European Organization for Research
and Treatment of Cancer (protocol EORTC 22042, ClinicalTri-
als.gov Identifier NCT00626730), has patients with atypical or
malignant meningioma being treated with adjuvant radiation
therapy following surgical resection. While we eagerly await the
FIGURE 5 | MRI venogram. An MRI venogram demonstrated that the left
transverse sinus was atretic and the right transverse sinus was dominant.
results of these trials to optimize patient care, current manage-
ment of patients is based on the best evidence available. While
randomized trials do not exist, adjuvant radiation therapy imme-
diately following initial surgery for WHO Grade II and III menin-
gioma should be considered given the high rate of local recurrence
(Figure 1). Radiation should also be administered for patients
undergoing subtotal resection. These recommendations are con-
gruent with National Comprehensive Cancer Network Clinical
Practice Guidelines in Oncology (37).
CASE ILLUSTRATION 1
A 50-year-old female initially presented 8 years prior with a
5 cm× 5.5 cm× 5 cm enhancing parasagittal lesion with osseous
invasion and left sided motor weakness. She underwent a subtotal
resection; the pathological diagnosis was consistent with menin-
gioma WHO grade I with no atypical features and a MIB index
of 5% (38). Postoperatively, her weakness resolved, but 2 months
later she was found to have a new nodular enhancing com-
ponent in the inferior aspect of the resection site measuring
1.5 cm× 1.5 cm× 1.3 cm. She underwent intensity-modulated
radiation therapy 6000 cGy without complication. Six years fol-
lowing radiation, she presented with right-sided weakness and was
found to have very aggressive interval growth of the residual tumor
(Figure 2). Given the suspicion that her tumor had undergone
either atypical or anaplastic transformation, she underwent subto-
tal resection and placement of interstitial brachytherapy I(125)
seeds (Figures 3 and 4). Pathological diagnosis of the tumor
removed at the time of the second surgery revealed an atypical
meningioma, WHO Grade II of III with high cell density, archi-
tectural sheeting, and prominent nucleoli. This case highlights
the unique scenario of tumor of progression following treatment.
When atypical or malignant progression is suspected on pre-
operative imaging, brachytherapy can be considered at the time
of re-operation.
CASE ILLUSTRATION 2
A 60-year-old woman underwent gross total resection of her
right frontal convexity meningioma; and received post-operative
FIGURE 6 | Radiosurgery dosimetry. Dosimetry map for proton radiosurgical treatment of a torcular meningioma.
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radiation for the pathological diagnosis of atypical meningioma.
Two years later on routine follow-up, she was found to have a
new lesion invading the torcula. An MRI venogram was obtained
that demonstrated an unfavorable dural sinus configuration; her
left transverse sinus was atretic and her right transverse sinus was
dominant (Figure 5).
In weighing the risks and benefits of open surgery versus stereo-
tactic radiosurgery, it was decided that radiosurgery would be
the best treatment option for her. She underwent stereotactic
radiosurgery to the lesion, presumed to be an atypical menin-
gioma based on her previously pathology from the first surgery
(Figure 6). From a technical aspect, given the sinus involvement
on pre-operative imaging, it was likely that a gross total resection
would not be able to be achieved and any tumor left remaining
on the sinus would need to be treated with radiation, regard-
less. Stereotactic radiosurgery provides the benefit of treating the
entire lesion while minimizing the risk of a potentially catastrophic
venous infarct or hemorrhage associated with open surgery.
CONCLUSION
World Health Organization grade II and III meningiomas can
have a malignant clinical course. Multidisciplinary strategies of
care involving aggressive surgical resection and post-operative
radiation therapy may reduce recurrence rates. Studies to assess
the optimal timing and modality of post-operative radiation are
underway.
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